SAN DIEGO, CALIFORNIA - iCFO Capital Global, Inc., recently partnered with Arise BioPharma to raise $20M from iCFO Capital Global investor network nationwide.
Arise BioPharma Inc. (Arise) is a wholly-owned subsidiary of Peptide Account LLC. Arise holds property rights to several late-stage compounds targeting neuro-degenerative illnesses. It is poised to enter a high-value Phase 2/3 clinical study in an orphan indication, namely Progressive Multifocal Leukocencephalopathy (PML) with prior clinical evidence in a proof of concept Phase 2a study and Emergency INDs.
Their current clinical study is centered around Progressive multifocal leukoencephalopathy (PML), a condition affecting the white matter of the brain. The root cause of this disease is an infection caused by the polyomavirus JC, which specifically targets the cells that produce myelin, the insulating material surrounding neurons, causing loss of coordination, speech, memory loss, and vision problems among other symptoms. This disease, known as PML, has no known cure and can be fatal within 2 months to 2 years of diagnosis. This would be an unmet clinical need for patients.
Dr. Gaytri Kachroo is an accomplished legal scholar with a PhD from the Harvard Law School. Dr. Kachroo is a highly accomplished general counsel and has acted in senior executive management roles for the past twenty (20) years in biopharma and finance. Prior successes have been marked in her experience as a high-profile congressional counsel, fraud litigator, international regulatory experience, and a former corporate transactional attorney in technology, life sciences, and finance.
For more information about the company, please contact: gaytri@peptideaccount.com
iCFO Capital Global, Inc. provides a platform for Entrepreneurs to connect with our Private Investors that makes direct debt and equity investment for early-stage and expand growth businesses. To learn more about how your business can secure the funding it needs, visit: https://www.icfocapital.com/